LAB International to hold fourth quarter and fiscal 2006 conference call and webcast



    Toronto Stock Exchange Symbol: LAB

    MONTREAL, March 20 /CNW Telbec/ - LAB International Inc. (TSX: LAB,
Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), a drug development company focused
on developing therapies for the inhalation and pain markets, today announced
that it will report financial results for the fourth quarter and fiscal 2006
ended December 31, 2006 on Monday March 26, 2007.
    LAB will host a conference call at 10:00 a.m., on Monday March 26, 2007.
Interested parties may also access the conference call by webcast at
www.labinc.ca.
    The telephone number to access the conference call is 1-800-591-7539. A
replay of the call will be available until Monday April 2, 2007. The telephone
numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code
number 21224056#.

    About LAB International

    LAB International is an integrated drug development company focused on
the growing multi-billion dollar inhalation market. Its lead product, for the
treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation
delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its
pipeline also includes therapeutics for asthma, COPD, and growth hormone
deficiencies.
    LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the
symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol
"LD9.F" and on XETRA under the symbol "LD9.DE" with 82.3 million shares
outstanding.

    This news release contains certain forward-looking statements that
reflect the current views and/or expectations of LAB International Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
    %SEDAR: 00003466EF




For further information:

For further information: visit LAB's website at www.labinc.ca, or
contact: Frédéric Dumais, Vice-President, Investor Relations, (514) 315-3330
ext. 106, Fax: (514) 315-3325, dumaisf@labinc.ca

Organization Profile

Akela Pharma Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890